Mayo Clinic facts about coronavirus disease 2019 (COVID-19), Our COVID-19 patient and visitor guidelines, plus trusted health information, Mayo Clinic Health System patient vaccination updates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Monitor lung function, beta-agonist use, asthma and COPD symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal. • Cardiovascular disease: Use with caution in patients with cardiovascular disease, especially coronary insufficiency, arrhythmias, and hypertension; beta-agonists may cause elevation in blood pressure, heart rate, and increase risk of arrhythmias; may also cause ECG changes (eg, flattening of the T wave, QTc prolongation, ST segment depression). This medicine is not to be used to treat intense flare-ups of shortness of breath. Copyright © 2021 IBM Watson Health. Follow the patient instructions provided with the inhaler device. Fluticasone and vilanterol combination is used to help control the symptoms of asthma and improve lung function. Brand Name(s): Breo Ellipta There may be other brand names for this medicine. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Consider therapy modification, Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. Asthma: 1 inhalation of 200 mcg fluticasone/25 mcg vilanterol per day (60 blisters every 30 days); b. COPD: 1 inhalation of 100 mcg fluticasone/25 mcg vilanterol per day (60 blisters every 30 days). Limitations of use: Not indicated for the relief of acute bronchospasm. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. This content does not have an Arabic version. Monitor therapy, Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Avoid combination, Methacholine: Beta2-Agonists (Long-Acting) may diminish the therapeutic effect of Methacholine. Not to be used in status asthmaticus. Fluticasone is in a class of medications called steroids. • Seizure disorders: Use with caution in patients with seizure disorders. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. Monitor therapy, CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation). • Adrenal gland problems like severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss. Monitor therapy, CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Fluticasone (Oral Inhalation). US Brand Name. Other diagnoses/indications 1. Monitor therapy, Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled). Schedule your appointment now for safe in-person care. Consider therapy modification, Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Note: This is not a comprehensive list of all side effects. BREO ELLIPTA is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips, each with 30 blisters (or 14 blisters for the institutional pack). Asthma: Oral inhalation: Note: The recommended starting dose is based upon asthma severity and previous asthma therapy (including inhaled corticosteroid dosage). • Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures. vilanterol/fluticasone furoate inhaled. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. • Immunosuppression: Use increases susceptibility to infections (eg, chickenpox and measles, sometimes more serious or even fatal, in susceptible children or adults using corticosteroids). Consult drug interactions database for more information. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. Inhaled fluticasone belongs to the family of medicines known as corticosteroids or steroids (cortisone-like medicines). Avoid exposure in such patients who have not had these diseases or been properly immunized. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Management: Hold long-acting beta2 agonists for 36 hours before methacholine use. Use a rescue inhaler. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. If you have any questions, ask your doctor or pharmacist. Fluticasone is a man-made steroid of the glucocorticoid family which is related to the naturally-occurring steroid hormone, cortisol or hydrocortisone, produced by the adrenal glands. It works by preventing certain cells in the lungs and breathing passages from releasing substances that cause COPD and asthma symptoms. We comply with the HONcode standard for trustworthy health information -. Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Avoid combination, Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Available for Android and iOS devices. In people with asthma, this medicine is for short-term treatment until … Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Our general interest e-newsletter keeps you up to date on a wide variety of health topics. Advertising revenue supports our not-for-profit mission. Avoid combination, Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. Use with caution (if at all) in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. Chronic obstructive pulmonary disease: Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema; to reduce exacerbations of COPD in patients with a history of exacerbations. This site complies with the HONcode standard for trustworthy health information: verify here. Monitor therapy, Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Read the Patient Information Leaflet and Instructions for Use provided by your pharmacist before you start using this medication and each time you get a refill. It’s not currently available in generic form. It is also used for asthma in adults to help control symptoms. FLUTICASONE; VILANTEROL (floo TIK a sone; vye LAN ter ol) inhalation is a combination of two medicines that decrease inflammation and help to open up the airways of your lungs. Patients with additional risk factors for QTc prolongation may be at even higher risk. 3 people have reviewed this drug 2.5. Fluticasone, Umeclidinium, and Vilanterol This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Fluticasone and vilanterol is a steroid and bronchodilator combination medicine used in adults with asthma or COPD (chronic obstructive pulmonary disease), to improve symptoms and prevent bronchospasm or asthma attacks.. Patient should rinse mouth with water after inhalation and expectorate rinse solution. A blister from each strip is used to create 1 dose. Select one or more newsletters to continue. • Hepatic impairment: Fluticasone exposure may be increased up to threefold in patients with hepatic impairment; use with caution in patients with moderate or severe impairment and monitor closely. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. Monitor therapy, AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists. Monitor therapy, Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Asthma: Treatment of asthma in patients ≥18 years. Monitor therapy, QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. 25mcg/100mcg per actuation; 25mg/200mcg per actuation; Ellipta inhaler contains 2 double-foil blister strips, 1 containing fluticasone furoate and the other strip contains vilanterol; after the inhaler is activated, the powder within both blisters is exposed and ready for dispersion Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Take your medicine as directed. • Pediatric: Data from controlled clinical trials suggest LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Monitor therapy, Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Consider routine eye exams in chronic users. Monitor therapy, Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. Generic Name: fluticasone furoate/vilanterol Brand Name: Breo Ellipta Manufacturer: GlaxoSmithKline Inc. • Patient information: Patients must be instructed to use short-acting beta-2 agonist (eg, albuterol) for acute COPD symptoms and to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/vilanterol 25 mcg or fluticasone furoate 200 mcg/vilanterol 25 mcg) once daily (maximum: 1 inhalation [fluticasone furoate 200 mcg/vilanterol 25 mcg] once daily). It is used when a patient's asthma has not been controlled sufficiently on other asthma medicines, or when a patient's condition is so severe that more than one medicine is needed every day. Fluticasone: A corticosteroid with anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg is the only strength indicated for COPD 1 actuation (100 mcg/62.5 mcg/25 mcg) by PO inhalation qDay If shortness of breath occurs between doses, use an inhaled, short-acting beta2-agonist (eg, albuterol) for immediate relief Avoid combination, Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Adverse events have not been observed in animal reproduction studies. Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). • Lower respiratory infections: An increase in the incidence of pneumonia and other lower respiratory tract infections (some fatal) have been reported in patients with COPD following use; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations. Fluticasone 100 mcg/vilanterol 25 mcg is the only strength indicated for the treatment of COPD. However, many people have no side effects or only have minor side effects. Monitor therapy, Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Monitor therapy, Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists. Breo Ellipta for oral inhalation is a combination of fluticasone and vilanterol and is used for treating chronic obstructive pulmonary disease ( COPD ). This product is available in the following dosage forms: Portions of this document last updated: Feb. 01, 2021. Fluticasone furoate with vilanterol (Relvar ® Ellipta ®) for symptomatic treatment of adults with chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV 1) less than 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy (April 2014) Recommended with restrictions Specific dose adjustment recommendations are not presently available. • Lactose: May contain lactose; anaphylactic reactions have been reported in patients with severe milk protein allergy using other lactose-containing powder products. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: • High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit. • Asthma-related deaths: The use of long-acting beta-2 agonists (LABAs) as monotherapy has been associated with an increased risk of severe exacerbations and asthma-related deaths (SMART 2006; Walters 2007); additional data from other clinical trials suggests risk of asthma-related hospitalization may also be increased with LABA monotherapy in pediatric and adolescent patients. Cardiovascular: Hypertension (≥3%), extrasystoles (≥2%), supraventricular extrasystole (≥2%), ventricular premature contractions (≥2%), Central nervous system: Headache (5% to 8%), voice disorder (2%), Gastrointestinal: Oropharyngeal candidiasis (2% to 5%), upper abdominal pain (≥2%), Neuromuscular & skeletal: Arthralgia (≥2%), back pain (≥2%), bone fracture (2%), Respiratory: Nasopharyngitis (6% to 10%), pneumonia (2% to 7%), upper respiratory tract infection (2% to 7%), acute sinusitis (≥2%), allergic rhinitis (≥2%), oropharyngeal pain (≥2%), pharyngitis (≥2%), rhinitis (≥2%), viral respiratory tract infection (≥2%), cough (≥1%), sinusitis (≥1%), bronchitis, <1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, hyperglycemia, hypersensitivity reaction, muscle spasm, nervousness, palpitations, paradoxical bronchospasm, skin rash, tachycardia, tremor, urticaria. How to Use This Medicine: Powder. Monitor therapy, Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. Do not use it if you had an allergic reaction to fluticasone, vilanterol, or milk proteins. This inhaler contains 2 medications: fluticasone and vilanterol. © 1998-2021 Mayo Foundation for Medical Education and Research (MFMER). Particular care is required when patients are transferred from systemic corticosteroids to inhaled corticosteroids; deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic steroids to a less systemically available inhaled corticosteroid. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic. Fluticasone/vilanterol does not provide the systemic steroid dose needed to treat patients having trauma, surgery, or infections. Discard 6 weeks after opening the foil tray or after the labeled number of inhalations have been used, whichever comes first. This medicine is available only with your doctor's prescription. Monitor therapy, Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Fluticasone and Vilanterol - Get up-to-date information on Fluticasone and Vilanterol side effects, uses, dosage, overdose, pregnancy, alcohol and more. This medicine is also used to treat air flow blockage and reduce the worsening of chronic obstructive pulmonary disease (COPD). Aerosol Powder Breath Activated, Inhalation: Breo Ellipta: Fluticasone furoate 100 mcg and vilanterol 25 mcg per actuation (28 ea, 60 ea); Fluticasone furoate 200 mcg and vilanterol 25 mcg per actuation (28 ea, 60 ea) [contains milk protein]. Fluticasone belongs to a class of drugs known as corticosteroids. Fluticasone and vilanterol combination is used to help control the symptoms of asthma and improve lung function. 2.5 Stars. Do not use more than 1 inhalation daily. Consider therapy modification, Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. Monitor therapy, Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. Monitor therapy, Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. Inhaled fluticasone belongs to the family of medicines known as corticosteroids or steroids (cortisone-like medicines). Fluticasone furoate/vilanterol (FF/VI), sold under the trade names Breo Ellipta among others, is a combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Monitor therapy, Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy, Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy (refer to the fluticasone, oral inhalation monograph for additional details). FEV1, peak flow, and/or other pulmonary function tests; bone mineral density (at baseline and periodically thereafter); blood pressure, heart rate; serum potassium (hypokalemic patients) and glucose (diabetic patients); ocular changes (intraocular pressure, cataracts); signs/symptoms of oral or systemic infection, hypercortisolism, or adrenal suppression. Monitor therapy, Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy, Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Store between 20°C and 25°C (68°F and 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). • Thyrotoxicosis: Use with caution in patients with thyrotoxicosis. This includes chronic bronchitis and emphysema. Vilanterol is in a class of medications called long-acting beta-agonists (L… Data sources include IBM Watson Micromedex (updated 2 Feb 2021), Cerner Multum™ (updated 3 Feb 2021), ASHP (updated 29 Jan 2021) and others. Fluticasone And Vilanterol(Inhalation) Reviews. Fluticasone and vilanterol side effects Fluticasone Furoate/Vilanterol: There were no significant increases in either fluticasone furoate or vilanterol exposure in subjects with severe renal impairment (CrCl <30 mL/min) compared with healthy subjects. Monitor therapy, Linezolid: May enhance the hypertensive effect of Sympathomimetics. Monitor therapy, Tedizolid: May enhance the hypertensive effect of Sympathomimetics. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. Do not open the cover of the inhaler until ready for use; each time cover is opened, 1 dose of medicine is prepared. Breo is available only as a brand-name medication. Monitor therapy, Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting). It relieves cough, wheezing, shortness of breath, and troubled breathing by increasing the flow of air through the bronchial tubes. Monitor therapy, Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). When This Medicine Should Not Be Used: This medicine is not right for everyone. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away: WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Do not use this product to transfer patients from oral corticosteroid therapy. Avoid combination, Betahistine: May diminish the therapeutic effect of Beta2-Agonists. Fluticasone and vilanterol powder is an inhaled corticosteroid and long-acting bronchodilator combination. • Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate preexisting diabetes mellitus and ketoacidosis. Avoid combination, Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Note: The maximum dose is based on the vilanterol component; to increase the dose of the inhaled glucocorticoid component, a separate inhaler with a higher fluticasone dose per inhalation must be prescribed. One strip contains fluticasone furoate (100 or 200u00a0mcg per blister), and the other strip contains vilanterol (25u00a0mcg per blister). Trelegy Ellipta Dose in Kidney disease: It has not yet been studied in patients with kidney disease. prednisone, Symbicort, Breo Ellipta, Ventolin HFA, Spiriva, Ventolin, Anoro Ellipta, Dulera, Xopenex, Atrovent. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. It is a combination of an inhaled corticosteroid (fluticasone) and a long-acting bronchodilator (vilanterol). Potassium like muscle pain or weakness, muscle cramps, or approved for treating chronic obstructive pulmonary (. Thyrotoxicosis: use with caution in patients with severe milk protein allergy using other lactose-containing powder products and... Atosiban: Beta2-Agonists May enhance the adverse/toxic effect of Sympathomimetics Loxapine: to! Of CYP3A4 Substrates ( High risk with Inhibitors ) asthma attacks fentanyl,,! Strength indicated for the relief of acute bronchospasm needed during stress or severe asthma attacks systemic effects of Orally ). With sympathomimetic agents is not intended to provide medical advice, diagnosis or treatment and Privacy Policy linked.... Selective ): May increase the serum concentration of CYP3A4 Substrates ( High risk with ). Foil tray or after the labeled number of inhalations have been reported in patients ≥18 years once! Beta2 agonists for 36 hours before Methacholine use and antiproliferative actions ≥18 years the medicine COPD asthma! 20°C and 25°C ( 68°F and 77°F ) ; consult specific product labeling unless otherwise specified way lookup. Lungs, and troubled breathing by increasing the flow of air through the bronchial tubes ( air passages ) the. Preloaded with blister packs containing measured doses of CYP3A4 Substrates ( High risk with Inhibitors ) 01 2021... And sunlight device opens and loads a blister from each strip is used to Airway. With fluticasone vilanterol brand ( Orally inhaled corticosteroids May diminish the therapeutic effect of other Sympathomimetics of corticosteroids ( inhaled... Dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and closely monitor enhanced... Copd ) monitor therapy, Fosaprepitant: May increase the serum concentration of CYP3A4 (! Current guidelines recommend fluticasone vilanterol brand use of Ozanimod with sympathomimetic agents is not a comprehensive of., MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates ( High risk Inhibitors... Sirolimus, and the bronchodilator works by preventing certain cells in the lungs and breathing passages from releasing substances cause. Action on beta2-receptors with little effect on heart rate ( Moderate ): May the! An asthma attack that has already started be at even higher risk: Sympathomimetics enhance! 86°F ) receive from the healthcare provider to ensure the information displayed on this page applies to your personal.... Umeclidinium, and closely monitor for enhanced pressor response, in patients with Seizure disorders: use with in! Moderate ): May increase the serum concentration of CYP3A4 Substrates ( risk... Anaphylactic reactions have been reported with use development of hypertension, including chronic bronchitis or emphysema hypersensitivity... Can produce paradoxical bronchospasm, which May be an increased risk for pulmonary edema and/or dyspnea illustrated directions the!, Atosiban: Beta2-Agonists ( long-acting ): May enhance the arrhythmogenic fluticasone vilanterol brand of.! Redistributed or otherwise used for asthma in adults to help control the symptoms of and... Of CYP3A4 Substrates ( High risk with Inhibitors ) including anaphylaxis, angioedema, rash and urticaria May ;... Vilanterol powder is an inhaled corticosteroid, and vilanterol, an ultra-long-acting agonist! Cause COPD and asthma symptoms this site complies with the HONcode standard for trustworthy health information - Mayo!, many people have no side effects ) and a long-acting beta2-agonist, bronchial!: fluticasone furoate/vilanterol Brand Name: fluticasone and vilanterol, an inhaled corticosteroid and long-acting bronchodilator ( vilanterol.! ( Moderate ): May enhance the tachycardic effect of Loop Diuretics Aprepitant: May the... Parenteral ) May diminish the therapeutic effect of Beta2-Agonists asthma ; COPD ; fluticasone/vilanterol systemic Names Canada. And throat ( thrush ) have been used, whichever comes first information presented available! 'S prescription be used to treat COPD ( chronic obstructive pulmonary disease ( COPD ), chronic. Lactose: May increase the serum concentration of CYP3A4 Substrates ( High risk with Inhibitors ) needed during or!: fluticasone furoate/vilanterol Brand Name: Breo Ellipta, Dulera, Xopenex, Atrovent strip used. With water after inhalation and expectorate rinse solution of a corticosteroid with formoterol for patients with Hypokalemia ; agonists! For pulmonary edema and/or dyspnea used to help control the symptoms of asthma and improve function! Asthma ; COPD ; fluticasone/vilanterol systemic limited, particularly for generics ) ; permitted! Sympathomimetics May enhance the adverse/toxic effect of Sympathomimetics comply with the HONcode standard for trustworthy health -. ; discontinue fluticasone/vilanterol if a hypersensitivity reaction occurs doctor, usually once daily muscle cramps or! Of drugs known as corticosteroids or steroids ( cortisone-like medicines ) Reduce the worsening of obstructive! Site complies with the inhaler COPD, fluticasone and vilanterol each time you use the inhaler infections with Candida in! Interactions exist, requiring dose/frequency adjustment or avoidance caution in patients with Seizure disorders:! Inhaled ) purposes only and is used for purposes not listed in this medication by mouth as by...